Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
empagliflozin + verapamil
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Empagliflozin + verapamil** is an experimental, unapproved drug combination consisting of empagliflozin (code name BI 10773), a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), and verapamil, a calcium channel blocker of the phenylalkylamine class used for hypertension, angina, and arrhythmias. Empagliflozin promotes glucosuria to lower plasma glucose, while verapamil inhibits voltage-dependent calcium channels, reducing vascular tone and cardiac contractility. The combination is being studied for potential pharmacokinetic and pharmacodynamic interactions, with empagliflozin developed for type 2 diabetes mellitus, and verapamil for cardiovascular indications[2][5][8].
- Other names
- empagliflozin + verapamilBI 10773 + verapamil
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)SGLT2 (Sodium-glucose cotransporter protein subunit 2)SLC5A1 (Sodium Glucose Cotransporter 1)
Beyond the preview
Go deeper on empagliflozin + verapamil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on empagliflozin + verapamil.